Structure activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction

被引：14
作者：
Vo, Duc Duy [1 ]
Gautier, Fabien [2 ,3 ]
Juin, Philippe [2 ]
Gree, Rene [1 ]
机构：
[1] Univ Rennes 1, Lab Sci Chim Rennes, CNRS UMR 6226, F-35042 Rennes, France
[2] Univ Nantes, CRCNA INSERM U892, F-44007 Nantes 1, France
[3] Ctr Rech Cancerol, Inst Cancerol Ouest, Nantes, France
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2012年 / 51卷
关键词：
Phenol; Bax; Bcl-xL; Apoptosis; BRET; Cancer; BCL-2; FAMILY-MEMBERS; SMALL-MOLECULE INHIBITORS; PROGRAMMED CELL-DEATH; BH3 MIMETIC ABT-737; CANCER; APOPTOSIS; TARGETS; MCL-1; SENSITIVITY; MECHANISMS;
D O I：
10.1016/j.ejmech.2012.02.036
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
This paper describes the synthesis of nine selected diaryl/heteroaryl-containing phenol and polyphenol derivatives which have been evaluated against Bax/Bcl-xL interaction in comparison with ABT-737. Using a BRET assay, six of these derivatives exhibit activity comparable to ABT-737 to disrupt Bax/Bcl-xL interaction. These preliminary results demonstrate that such polyphenol-derived molecules are attractive compounds regarding anticancer activity and that the phenol at position 3 is important regarding disruption of Bax/Bcl-xL interaction. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：286 / 293
页数：8
相关论文
共 43 条
  • [11] James DF, 2006, J CLIN ONCOL, V24, p362S
  • [12] James DF, 2005, BLOOD, V106, p835A
  • [13] Shooting at survivors: Bcl-2 family members as drug targets for cancer
    Juin, P
    Geneste, O
    Raimbaud, E
    Hickman, JA
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1644 (2-3): : 251 - 260
  • [14] Polyphenols and cancer cell growth
    Kampa, M.
    Nifli, A. -P.
    Notas, G.
    Castanas, E.
    [J]. REVIEWS OF PHYSIOLOGY, BIOCHEMISTRY AND PHARMACOLOGY, VOL 159, 2007, 159 : 79 - 113
  • [15] Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
    Konopleva, Marina
    Contractor, Rooha
    Tsao, Twee
    Samudio, Ismael
    Ruvalo, Peter P.
    Kitada, Shinichi
    Deng, Xingming
    Zhai, Dayong
    Shi, Yue-Xi
    Sneed, Thomas
    Verhaegen, Monique
    Soengas, Maria
    Ruvolo, Vivian R.
    McQueen, Teresa
    Schober, Wendy D.
    Watt, Julie C.
    Jiffar, Tilahun
    Ling, Xiaoyang
    Marini, Frank C.
    Harris, David
    Dietrich, Martin
    Estrov, Zeev
    McCubrey, James
    May, W. Stratford
    Reed, John C.
    Andreeff, Michael
    [J]. CANCER CELL, 2006, 10 (05) : 375 - 388
  • [16] Drugs targeting Bcl-2 family members as an emerging strategy in cancer
    Leber, Brian
    Geng, Fei
    Kale, Justin
    Andrews, David W.
    [J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2010, 12
  • [17] BCL-2 family antagonists for cancer therapy
    Lessene, Guillaume
    Czabotar, Peter E.
    Colman, Peter M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) : 989 - 1000
  • [18] The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death
    Manero, F
    Gautier, F
    Gallenne, T
    Cauquil, N
    Grée, D
    Cartron, PFO
    Geneste, O
    Grée, R
    Vallette, FOM
    Juin, P
    [J]. CANCER RESEARCH, 2006, 66 (05) : 2757 - 2764
  • [19] Bcl-2 family members as molecular targets in cancer therapy
    Marzo, Isabel
    Naval, Javier
    [J]. BIOCHEMICAL PHARMACOLOGY, 2008, 76 (08) : 939 - 946
  • [20] Apoptosis in development
    Meier, P
    Finch, A
    Evan, G
    [J]. NATURE, 2000, 407 (6805) : 796 - 801
12345